nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

01.06.2021 | editorial

Immunotherapy revisited

verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Excerpt

Immunotherapy has revolutionized cancer treatment during the last few years. Impressive long-term survival rates (beyond 5 years) even in deadly diseases such as metastatic lung cancer or malignant melanoma were achieved by checkpoint inhibitor (CPI) therapy. …

Nächster Artikel Treatment approaches towards physical activity – malnutrition – cognitive impairment

Zila N, Hoeller C, Paulitschke V. Novel immune checkpoints beyond PD‑1 in advanced melanoma. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00699-0.CrossRef

Umut Ö, Gottschlich A, Endres S, Kobold S. CAR T cell therapy in solid tumors: a short review. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00703-7.CrossRef

Heller G. DNA methylation as predictive marker of response to immunotherapy?. memo. 2021;14(2). https://doi.org/10.1007/s12254-021-00696-3.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46.CrossRef

Jacobson C, Locke FL, Ghobadi A, et al Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Blood 2020; 136 (Supplement 1): 40–42. https://doi.org/10.1182/blood-2020-134362.

Aguiar PN Jr., Santoro IL, Tadokoro H, et al. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2016;8:479–88.CrossRef

Titel: Immunotherapy revisited
verfasst von: Assoc. Prof. PD Dr. Thorsten Füreder
Publikationsdatum: 01.06.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00711-7

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Unique gastrointestinal stromal tumor with PDGFRA D842Y mutation—evaluation of in vivo sensitivity to imatinib

ESMO virtual congress 2020—highlights NSCLC

Update ESMO: gastric and esophageal cancer

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

Importance of performance status and physical activity in cancer patients

Novel immune checkpoints beyond PD-1 in advanced melanoma